In addition, we show that curcumin can significantly inhibit tumor growth via CaM downregulation and that combining curcumin with FBXL2 activator nebivolol markedly inhibits EGFRT790M/C797S expression and overcomes EGFRT790M/C797S-mediated osimertinib resistance in xenograft mouse model. Here, FBXL2 is linked to neoplasm.